| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/01/2005 | CA2138287C N-substituted azabicycloheptane derivatives, the preparation and use thereof |
| 02/28/2005 | CA2438744A1 Method to diagnose and treat degenerative joint disease |
| 02/26/2005 | WO2006046934A2 Osteoclastogenesis inhibitors and uses thereof |
| 02/26/2005 | CA2536380A1 Osteoclastogenesis inhibitors and uses thereof |
| 02/24/2005 | WO2005017484A2 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 02/24/2005 | WO2005017190A2 Mitotic kinesin inhibitors |
| 02/24/2005 | WO2005017185A2 HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS |
| 02/24/2005 | WO2005017160A2 Mobilization of hematopoietic cells |
| 02/24/2005 | WO2005017129A1 Phosphoramide and uses thereof |
| 02/24/2005 | WO2005017127A2 Rna interference compositions and methods |
| 02/24/2005 | WO2005017102A2 Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| 02/24/2005 | WO2005017098A2 AMPHIPATHIC AND POLYCATIONIC COMPOUNDS FOR DELIVERING siRNA |
| 02/24/2005 | WO2005017094A2 N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| 02/24/2005 | WO2005016960A2 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 02/24/2005 | WO2005016958A2 Compounds for treating tumors |
| 02/24/2005 | WO2005016942A1 Organophosphoric 4-iminohydantoin derivatives |
| 02/24/2005 | WO2005016932A1 Pyranobenzothiophene derivatives to treat infection with hepatitis c virus |
| 02/24/2005 | WO2005016928A1 Imidazopyridine derivatives |
| 02/24/2005 | WO2005016927A1 Nitrogenous condensed-ring compound and use thereof as hiv integrase inhibitor |
| 02/24/2005 | WO2005016920A1 Pyrrole compositions useful as inhibitors of c-met |
| 02/24/2005 | WO2005016918A2 Heterocyclic n-aryl carboxamides as cytokine inhibitors |
| 02/24/2005 | WO2005016913A1 Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| 02/24/2005 | WO2005016911A1 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| 02/24/2005 | WO2005016909A1 Substituted thiophenes and uses thereof |
| 02/24/2005 | WO2005016895A1 Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thinone, its preparation and a depigmentation compositon containing the same as an effective component |
| 02/24/2005 | WO2005016893A2 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| 02/24/2005 | WO2005016892A1 Gabanergic modulators |
| 02/24/2005 | WO2005016888A1 Probe for diseases wth amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change |
| 02/24/2005 | WO2005016885A2 COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
| 02/24/2005 | WO2005016884A1 Cyclopropyl derivatives as nk3 receptor antagonists |
| 02/24/2005 | WO2005016883A2 Acrylamide derivatives as vla-1 integrin antagonists and uses thereof |
| 02/24/2005 | WO2005016879A2 Cyclic pyrazinoylguanidine sodium channel blockers |
| 02/24/2005 | WO2005016877A2 Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 02/24/2005 | WO2005016876A2 Cyclic amine bace-1 inhibitors having a benzamide substituent |
| 02/24/2005 | WO2005016875A2 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors |
| 02/24/2005 | WO2005016872A1 Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| 02/24/2005 | WO2005016859A2 Proteasome inhibitors and methods of using the same |
| 02/24/2005 | WO2005016528A2 6-substituted anilino purines as rtk inhibitors |
| 02/24/2005 | WO2005016514A2 Combinatorial synthesis on support |
| 02/24/2005 | WO2005016400A1 Endoluminal prosthesis comprising a therapeutic agent |
| 02/24/2005 | WO2005016386A1 Improved therapeutic protocols |
| 02/24/2005 | WO2005016384A1 Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change |
| 02/24/2005 | WO2005016383A1 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
| 02/24/2005 | WO2005016377A1 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/24/2005 | WO2005016370A1 Method of treating viral infections |
| 02/24/2005 | WO2005016363A1 Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil |
| 02/24/2005 | WO2005016360A1 Topical compositions of ammonium lactate |
| 02/24/2005 | WO2005016359A1 Method of promoting remyelination |
| 02/24/2005 | WO2005016358A1 Anthelmintic formulations |
| 02/24/2005 | WO2005016357A1 Improved anthelmintic formulations |
| 02/24/2005 | WO2005016356A1 Improved anthelmintic formulations |
| 02/24/2005 | WO2005016355A1 Intravascular delivery of non-viral nucleic acid |
| 02/24/2005 | WO2005016354A1 Diflunisal for the treatment of cancer |
| 02/24/2005 | WO2005016353A1 Topical ointment for vesicating chemical warfare agents |
| 02/24/2005 | WO2005016352A1 AMINO ACID AND PEPTIDE-MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH ß2 ADRENERGIC AGONISTS |
| 02/24/2005 | WO2005016351A1 Novel use of cannabinoid receptor agonist |
| 02/24/2005 | WO2005016350A1 Ammonium salts of ornithine derivatives for treating inflammatory diseases |
| 02/24/2005 | WO2005016349A1 Methods of inhibiting leukocyte accumulation |
| 02/24/2005 | WO2005016348A1 Method of inhibiting immune responses stimulated by an endogenous factor |
| 02/24/2005 | WO2005016347A1 Dosing schedule for erbb2 anticancer agents |
| 02/24/2005 | WO2005016345A1 Multivitamin syrup for children or young adults |
| 02/24/2005 | WO2005016342A1 Sir2 regulation |
| 02/24/2005 | WO2005016341A1 Extended release analgesic for pain control |
| 02/24/2005 | WO2005016340A1 Furanone derivatives |
| 02/24/2005 | WO2005016339A1 Methods for the treatment of parkinson's disease |
| 02/24/2005 | WO2005016338A1 Use of 5-ht2b receptor antagonists for the treatment of congestive heart failure |
| 02/24/2005 | WO2005016337A1 Channel blocking compounds |
| 02/24/2005 | WO2005016336A1 Method and composition for treating burned skin |
| 02/24/2005 | WO2005016334A1 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1 |
| 02/24/2005 | WO2005016333A1 Use of tyrphostins in treating restenosis |
| 02/24/2005 | WO2005016332A1 Compositions and methods for treating gastrointestinal conditions |
| 02/24/2005 | WO2005016331A1 Therapeutic agent for neuropathic pain containing n-(benzoyl)amino acid derivative as active ingredient |
| 02/24/2005 | WO2005016330A1 Methods and materials for treating conditions associated with metabolic disorders |
| 02/24/2005 | WO2005016329A1 Topical compositions of urea and ammonium lactate |
| 02/24/2005 | WO2005016328A1 Topical compositions of urea |
| 02/24/2005 | WO2005016327A2 Treatment of sleep disorders with cholinesterase inhibitors |
| 02/24/2005 | WO2005016326A2 Analogs of thalidomide as potential angiogenesis inhibitors |
| 02/24/2005 | WO2005016325A2 CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF |
| 02/24/2005 | WO2005016324A1 Material for aneurysm curing |
| 02/24/2005 | WO2005016323A2 Use of c-kit inhibitors for treating type ii diabetes |
| 02/24/2005 | WO2005016322A2 Pharmaceutical compositions of lavendustin |
| 02/24/2005 | WO2005016320A1 Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil |
| 02/24/2005 | WO2005016319A2 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| 02/24/2005 | WO2005016315A1 Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler |
| 02/24/2005 | WO2005016314A1 Form of administration secured against misuse |
| 02/24/2005 | WO2005016313A1 Dosage form that is safeguarded from abuse |
| 02/24/2005 | WO2005016310A1 Novel metaxalone compositions |
| 02/24/2005 | WO2005016308A1 Macrolides containing oil-in-water emulsions |
| 02/24/2005 | WO2005016307A1 Steroidal compositions containing hydroxycarboxylic acids and methods of using the same |
| 02/24/2005 | WO2005016306A2 Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
| 02/24/2005 | WO2005016297A1 Hair regenerator |
| 02/24/2005 | WO2005016288A2 Methods and compositions for treatment of viral diseases |
| 02/24/2005 | WO2005016286A2 Pyrazine modulators of cannabinoid receptors |
| 02/24/2005 | WO2005016285A2 Compositions and methods for inhibiting slit protein and glypican interactions |
| 02/24/2005 | WO2005016277A2 Arylsulfonamidobenzylic compounds |
| 02/24/2005 | WO2005016276A2 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
| 02/24/2005 | WO2005016275A2 Formulations containing an immune response modifier |
| 02/24/2005 | WO2005016273A2 Infection prophylaxis using immune response modifier compounds |
| 02/24/2005 | WO2005016272A2 Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| 02/24/2005 | WO2005016271A2 Composition comprising a zeolite compound for treatment of diseases |